

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chew, Anne; Denton, R. Rex; Duda, Amy; Nandabalan, Krishnan;

Stephens, Joel Claiborne; and Windemuth, Andreas K.

Application No.: To be determined

Group No.:

1646

Filed: November 9, 2001

Prema Mertz Examiner:

For: Drug Target Isogenes: Polymorphisms in the Interleukin 4 Receptor Alpha Gene

Assistant Commissioner for Patents Washington, D.C. 20231

PRELIMINARY AMENDMENT TO CLAIMS (37 C.F.R. 1.121 and M.P.E.P. 714.09)

This application is a division of pending PCT application PCT/US00/19094. Prior to calculating the filing fee, it is respectfully requested that the claims be amended as indicated below.

The differences between the claims as filed and amended are shown in the attached copies of the claims, as filed, with underlining indicating added material and brackets indicating deleted material. A summary of the claim amendments and support therefore is set forth below:

IN THE CLAIMS

Claim Number	Action	Support	
1, 3-10	Cancelled		(Renumbered 1-9)
11	Amended	Claim 10, as filed	(Renumbered 10)
12-20	Cancelled		(Renumbered 11-19)
21-22, 24-27	Unchanged		(Renumbered 20-25)

REMARKS

This amendment cancels claims 1, 3-10, and 12-20, without prejudice or disclaimer, that were examined in the International phase of this application. The cancelled subject matter is being pursued in a separate National Stage application filed concurrently herewith.

Replacement pages 74-75 are attached hereto. Applicants respectfully request acceptance of these claim amendments and that examination be based thereon.

Should any questions arise, or if Applicants or Applicants Agent can facilitate examination of this Application, please contact the undersigned Agent at the phone number below.

Respectfully submitted,

Sandra L. Shaner

Registration Number: 47,934

Genaissance Pharmaceuticals, Inc.

Five Science Park

New Haven, CT 06511

USA

Tel. No. 203-786-3468

s.shaner@genaissance.com